Latest Health stories from Life.
Veradermics has reported positive results from its late-stage trial for a new hair loss drug, positioning itself as a leading contender in a rapidly growing market.
Motif Neurotech has received FDA approval to commence an initial feasibility trial for a brain implant aimed at treating depression, marking a significant step in neurotechnology.
A recent study indicates that less than 50% of NIH-funded research papers include analysis or reporting of data by sex, highlighting a significant gap in research practices.
An integrative medicine doctor, who is married to the acting U.S. attorney general, has been appointed to a significant NIH advisory council responsible for funding decisions.
Nancy Cox, a prominent figure in influenza research and a veteran at the CDC, has passed away at the age of 77, leaving behind a significant legacy in public health.
In the podcast "Drug Story," host Thomas Goetz discusses how society often misuses medications like Ambien and Ozempic, highlighting a disconnect between drug use and bodily needs.
The Medicaid Enrollment and Unwinding Tracker provides updated data on state renewals and disenrollments as the unwinding period progresses.
The FDA is set to expedite the review process for three psychedelics as potential treatments for mental health issues, influenced by changing political attitudes.
Eli Lilly's decision to invest $3.2 billion in a struggling biotech startup raises questions about the potential the pharma giant sees in the company. Insights from Bryan Roberts may shed light on this move.
The Utah Medical Board has requested an immediate suspension of a pilot program that utilizes an AI bot for prescription renewals, citing significant backlash.
The pharmaceutical industry continues to see a dynamic shift with various new hires, departures, and promotions. Here’s a look at the latest personnel changes.
Today's health news highlights the growth of an international childhood vaccine campaign alongside a shift in GOP drug policy, signaling significant changes in public health efforts.
President Trump has finalized a series of drug pricing agreements, with the last deal involving Regeneron, marking the conclusion of 17 agreements pursued by the White House.
A multiple sclerosis treatment from Sanofi has received a positive review in Europe, marking a notable shift after its rejection by the FDA last year.
The increasing reliance on guest editors has raised alarms in the academic community, particularly following a recent retraction by a genetics journal of a nearly complete special issue.
Dawn Zuidegeest-Craft shares her experience of starting medical school at 69 and now preparing for residency at 72, highlighting the challenges and lessons learned.
The treatment of health and science reporting as optional is a significant oversight that impacts public health.
The latest STATus Report features a discussion on the implications of Trump's executive order regarding psychedelics, highlighting the evolving landscape of mental health treatments.
This week on "The Readout LOUD," we delve into a CAR-T biotech's significant turnaround and examine the strategies employed by drugmakers to increase prescriptions. Tune in for insights.
A recent mouse study suggests that the heart's relentless beating may create conditions that are unfavorable for cancer development.